Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHESTNUT: Tenecteplase in Acute Ischemic Stroke Beyond 4.5 Hours
NCT06994975Phase 3Recruiting
- Sponsor
- Huashan Hospital
- Start
- Nov 2025
- Primary completion
- Mar 2028
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tenecteplase in ischemic stroke (2 arms), sponsored by Huashan Hospital. Primary endpoint: Proportion of Participants Achieving Excellent Functional Outcome (mRS 0-1) at 90 days. Started Nov 2025; status: recruiting.
02
Drugs
tenecteplase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06994975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06994975.